Brazilian Plant Compounds Show Multi-Target Activity Against COVID-19
Researchers have discovered a group of natural compounds from a Brazilian tree that demonstrate promising activity against SARS-CoV-2, the virus responsible for COVID-19. These compounds, known as galloylquinic acids, were extracted from the leaves of Copaifera lucens Dwyer, a species native to Brazil’s Atlantic Forest. Unlike many traditional antivirals that target a single part of a virus, these molecules interfere with the virus on multiple fronts, potentially offering a more robust strategy to combat the infection.
- Source: Galloylquinic acids extracted from the leaves of the Copaifera lucens Dwyer tree.
- Mechanism: A multi-target approach that blocks viral entry, inhibits replication and reduces protein production.
- Benefit: The multi-target nature of these compounds reduces the likelihood of the virus developing resistance.
- Current Status: Laboratory findings; human clinical trials and testing in living organisms are the necessary next steps.
The Science Behind the Discovery
The investigation was led by Jairo Kenupp Bastos from the Ribeirão Preto School of Pharmaceutical Sciences at the University of São Paulo (FCFRP-USP). The team selected Copaifera lucens based on extensive previous research into the chemistry and medicinal properties of the Copaifera genus.
Galloylquinic acids are already known in the scientific community for their diverse biological effects. Previous studies have linked these compounds to antifungal and anticancer activities in both in vitro and in vivo settings. Similar compounds have demonstrated strong inhibition of HIV-1 in cell-based experiments while exhibiting lower toxicity than other tested substances.
How Galloylquinic Acids Combat SARS-CoV-2
According to findings published in Scientific Reports, these compounds do not rely on a single point of attack. Instead, they target several critical stages of the viral life cycle:
- Viral Entry: The compounds interact with the receptor-binding domain of the spike protein, which the virus uses to enter human cells.
- Immune Evasion: They target the papain-like protease (PLpro), an enzyme the virus employs to evade the body’s immune defenses.
- Replication: The compounds interfere with RNA polymerase, an enzyme essential for the virus to replicate its genetic material.
- Protein Production: The research indicates a reduction in the production of viral proteins.
Beyond direct antiviral activity, the compounds also exhibit anti-inflammatory and immunomodulatory properties. These effects may help regulate the immune response, which is particularly critical in managing severe cases of COVID-19.
“An important aspect revealed by this information is the multi-target mechanism of the compound, which reduces the likelihood of resistance developing. This is because many current antivirals act on only one viral protein, which promotes this effect,” says Bastos.
Rigorous Testing and Collaboration
With support from FAPESP, the research team employed a strict testing protocol to ensure safety and efficacy. The process began with cytotoxicity tests to confirm that the extracts were safe for cells before moving to antiviral assessments.
To quantify the effectiveness of the compounds, the team used plaque reduction assays to measure how well the substances neutralized viral particles. The results confirmed clear activity against SARS-CoV-2.
The study was a global collaborative effort. Mohamed Abdelsalam, an assistant professor of pharmacognosy and natural product chemistry at the Faculty of Pharmacy at the Delta University of Science and Technology in Egypt (also affiliated with the Pompeu Fabra University TecnoCampus in Barcelona, Spain), led the biological study. He worked alongside Professor Lamiaa A. Al-Madboly, Head of the Department of Microbiology at the Faculty of Pharmacy at Tanta University in Egypt, and Associate Professor Rasha M. El-Morsi from the Delta University of Science and Technology. The study also included collaboration with researchers from Alexandria University.
The Path Forward: Biodiversity as a Medical Resource
While these laboratory results are encouraging, they represent an early stage of development. Before galloylquinic acids can be transitioned into a clinical treatment, they must undergo testing in living organisms and rigorous human clinical trials.
This research underscores the strategic importance of biodiversity. The Atlantic Forest of Brazil serves as a rich reservoir for novel therapeutic compounds, proving that the exploration of natural sources remains a vital pathway for discovering the next generation of medicines.
Frequently Asked Questions
Can I use Copaifera lucens extracts to treat COVID-19 now?
No. These findings are based on laboratory tests. The compounds must undergo clinical trials and regulatory approval before they can be used as a medical treatment.
Why is a “multi-target” approach better than a single-target antiviral?
Viruses often mutate to bypass drugs that target a single protein. By attacking the virus at multiple stages—entry, replication, and protein production—it is much harder for the virus to develop resistance to the treatment.
What are galloylquinic acids?
They are natural chemical compounds found in the leaves of certain plants, including the Copaifera lucens tree, known for their antiviral, antifungal, and anticancer properties.